Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

TScan Therapeutics (TCRX) EBITDA (2020 - 2025)

Historic EBITDA for TScan Therapeutics (TCRX) over the last 6 years, with Q3 2025 value amounting to -$37.1 million.

  • TScan Therapeutics' EBITDA fell 1357.98% to -$37.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$148.7 million, marking a year-over-year decrease of 2444.29%. This contributed to the annual value of -$127.4 million for FY2024, which is 4285.01% down from last year.
  • As of Q3 2025, TScan Therapeutics' EBITDA stood at -$37.1 million, which was down 1357.98% from -$38.7 million recorded in Q2 2025.
  • TScan Therapeutics' EBITDA's 5-year high stood at -$7.9 million during Q1 2021, with a 5-year trough of -$38.7 million in Q2 2025.
  • Its 5-year average for EBITDA is -$24.0 million, with a median of -$22.7 million in 2023.
  • As far as peak fluctuations go, TScan Therapeutics' EBITDA crashed by 12091.76% in 2021, and later plummeted by 464.59% in 2022.
  • TScan Therapeutics' EBITDA (Quarter) stood at -$14.2 million in 2021, then crashed by 31.31% to -$18.6 million in 2022, then dropped by 14.52% to -$21.4 million in 2023, then crashed by 71.9% to -$36.7 million in 2024, then dropped by 0.93% to -$37.1 million in 2025.
  • Its EBITDA was -$37.1 million in Q3 2025, compared to -$38.7 million in Q2 2025 and -$36.2 million in Q1 2025.